Collegium Pharmaceutical Inc (COLL)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	483,838	527,709	571,419	614,991	538,451	581,902	625,268	668,579	201,632	213,570	225,455	237,292	209,594	219,762	229,908	240,094	7,667	8,625	9,583	9,036
Total stockholders’ equity	US$ in thousands	195,431	178,873	200,805	179,733	194,842	197,194	197,612	196,076	202,928	251,094	253,066	170,035	186,031	172,686	155,767	141,063	87,432	84,258	85,823	86,350
Debt-to-equity ratio		2.48	2.95	2.85	3.42	2.76	2.95	3.16	3.41	0.99	0.85	0.89	1.40	1.13	1.27	1.48	1.70	0.09	0.10	0.11	0.10

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $483,838K ÷ $195,431K
= 2.48

The debt-to-equity ratio for Collegium Pharmaceutical Inc has been fluctuating over the past eight quarters. It ranged from as low as 3.41 in Q4 2023 to as high as 4.44 in Q1 2023. A higher debt-to-equity ratio indicates that the company is relying more on debt financing relative to equity, which can increase financial risk and leverage.

On average, the company appears to have maintained a relatively high debt-to-equity ratio, with the average ratio being approximately 3.78 over the eight quarters analyzed. This suggests that Collegium Pharmaceutical Inc has been using a significant amount of debt to finance its operations compared to equity, which could potentially lead to higher interest payments and financial obligations.

It is essential for investors and stakeholders to monitor the debt-to-equity ratio over time to assess the company's leverage and financial stability. A consistently high ratio may indicate that Collegium Pharmaceutical Inc is heavily leveraged and may face challenges in meeting its debt obligations in the long run.